| 42.49 -0.28 (-0.65%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 54.7 |
1-year : | 59.22 |
| Resists | First : | 46.83 |
Second : | 50.7 |
| Pivot price | 43.09  |
|||
| Supports | First : | 40.56 |
Second : | 33.74 |
| MAs | MA(5) : | 42.83 |
MA(20) : | 44.07 |
| MA(100) : | 36.57 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 21.7 |
D(3) : | 23.3 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 50.7 | Low : | 22.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VCYT ] has closed above bottom band by 29.3%. Bollinger Bands are 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.71 - 42.97 | 42.97 - 43.16 |
| Low: | 41.28 - 41.62 | 41.62 - 41.88 |
| Close: | 42.04 - 42.55 | 42.55 - 42.92 |
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Thu, 25 Dec 2025
Veracyte, Inc. $VCYT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Tue, 23 Dec 2025
Is This the Right Time to Add Veracyte Stock to Your Portfolio? - sharewise.com
Thu, 18 Dec 2025
Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 30% Discount? - Yahoo Finance
Sun, 14 Dec 2025
Veracyte, Inc. $VCYT Shares Sold by Nikko Asset Management Americas Inc. - MarketBeat
Wed, 10 Dec 2025
Next Century Growth Investors LLC Lowers Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
Mon, 08 Dec 2025
Eastham (Veracyte director) sells $908k in VCYT stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 79 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 114.6 (%) |
| Shares Short | 5,710 (K) |
| Shares Short P.Month | 6,040 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.9 |
| Profit Margin | 6.1 % |
| Operating Margin | 17.5 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 2.4 % |
| Qtrly Rev. Growth | 13.8 % |
| Gross Profit (p.s.) | 4.42 |
| Sales Per Share | 6.26 |
| EBITDA (p.s.) | 0.93 |
| Qtrly Earnings Growth | 26.2 % |
| Operating Cash Flow | 108 (M) |
| Levered Free Cash Flow | 92 (M) |
| PE Ratio | 111.81 |
| PEG Ratio | 0 |
| Price to Book value | 2.67 |
| Price to Sales | 6.78 |
| Price to Cash Flow | 31.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|